. 2021 Dec 28;14(1):135. doi: 10.3390/cancers14010135

Table 4.

Numerical results for the optimization problem OP1. Anti-CTLA4 has been administered as mono-therapy (AC) and in combination with dendritic cell vaccine (AC + V). Both the immunotherapies have been tested by taking into account the general constraints defined in Section 2.5 and an additional constraint concerning the minimum time interval between two infusions ( $Δ_{t}$ ) fixed as 1 or 3 weeks. Column three and four list the infusion times and doses predicted by the model as the optimal schedules. The values $O_{1}$ and $O_{2}$ represent the two components of the optimization function, namely $O_{1} = \int_{t_{1}}^{t_{f}} T u m (t) d t$ and $O_{2} = T o x (t_{f}, I_{p} (t))$ .

Therapy	$Δ_{t}$	Infusion Times (Weeks)	Doses (mg/kg)	$O_{1}$	$O_{2}$
AC	1 week	$t_{1} = 0, t_{2} = 1,$ $t_{3} = 2, t_{4} = 4$	$d_{1} = 10, d_{2} = 7.5,$ $d_{3} = 4.5, d_{4} = 7$	354.47	0.57
AC + V	1 week	$t_{1} = 0, t_{2} = 1,$ $t_{3} = 2$	$d_{1} = 10, d_{2} = 7.5,$ $d_{3} = 4.5$	292.67	0.52
AC	3 weeks	$t_{1} = 0, t_{2} = 3,$ $t_{3} = 6$	$d_{1} = 10, d_{2} = 10,$ $d_{3} = 10$	483.01	0.63
AC + V	3 weeks	$t_{1} = 0, t_{2} = 3$ $t_{3} = 6$	$d_{1} = 10, d_{2} = 10$ $d_{3} = 4.5$	371.13	0.60